Clinical and Translational Allergy最新文献

{"title":"Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge","authors":"Bianca Olivieri,&nbsp;Ana Jimenez Gil,&nbsp;Kostadin Stoenchev,&nbsp;Stephen R. Durham,&nbsp;Guy Scadding","doi":"10.1002/clt2.12360","DOIUrl":"10.1002/clt2.12360","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nasal allergen challenge (NAC) is used to investigate the effects of allergen exposure and assess treatment efficacy in allergic rhinitis (AR). This study aims to establish dose-responses to NAC using licensed silver birch (SB) pollen and house dust mite (HDM) sublingual tablets as sources of the allergen extracts in participants with AR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixteen volunteers with HDM-induced perennial AR and 15 volunteers with SB pollen-induced seasonal rhinitis underwent a graded up-dosing NAC with extracts derived from HDM allergen (Acarizax®) and SB (Itulazax®) tablets, respectively. Total nasal symptom score (TNSS, range 0–12) and peak nasal inspiratory flow (PNIF) were recorded before, at 10 min and at the end of the NAC. The dose of each allergen that provoked a TNSS of at least 7 (“provoking dose 7”) in most allergic participants was identified. NACs using the “provoking dose 7” were performed on 5 non-allergic individuals to test for irritant effects. The “provoking dose 7” of HDM extract was used in a subgroup of two SB allergic, non-HDM allergic, volunteers, and vice versa for SB extract, to test for allergen specificity of the responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients experienced a TNSS of at least 7/12 at a median concentration of 1500 AU/mL for both SB pollen and HDM. The average decline in PNIF at this dose was 63.15% for SB and 63.99% for HDM. NACs using the 1500 AU/mL concentrations were performed on 5 non-allergic individuals with no symptomatic or PNIF response. 1500 AU/mL of HDM extract produced no symptoms in SB allergics nor 1500 AU/mL SB extract in HDM allergics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>For both SB and HDM extracts, the optimal allergen dose for NAC to cause a moderate-severity response (“provoking dose 7/12”) was 1500 AU/mL. Licensed sublingual allergen tablets provide a readily available and inexpensive source of SB and HDM extracts for use in future interventional studies in AR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12360","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic analysis reveals potential therapeutic targets for childhood asthma through Mendelian randomization","authors":"Yi-Qing Wu,&nbsp;Yi-Xin Cai,&nbsp;Xiao-Li Chen,&nbsp;Shang-Qin Chen,&nbsp;Xiu-Feng Huang,&nbsp;Zhen-Lang Lin","doi":"10.1002/clt2.12357","DOIUrl":"10.1002/clt2.12357","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asthma is the most common chronic disease among children and poses a significant threat to their health. This study aims to assess the relationship between various plasma proteins and childhood asthma, thereby identifying potential therapeutic targets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on publicly available genome-wide association study summary statistics, we employed a two-sample Mendelian randomization (MR) approach to elucidate the causal relationship between plasma proteins and asthma. Mediation analysis was then conducted to evaluate the indirect influence of plasma proteins on childhood asthma mediated through risk factors. Comprehensive analysis was also conducted to explore the association between plasma proteins and various phenotypes using the UK Biobank dataset.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MR analysis uncovered a causal relationship between 10 plasma proteins and childhood asthma. Elevated levels of seven proteins (TLR4, UBP25, CBR1, Rac GTPase-activating protein 1 [RGAP1], IL-21, MICB, and PDE4D) and decreased levels of three proteins (GSTO1, LIRB4 and PIGF) were associated with an increased risk of childhood asthma. Our findings further validated the connections between reported risk factors (body mass index, mood swings, hay fever or allergic rhinitis, and eczema or dermatitis) and childhood asthma. Mediation analysis revealed the influence of proteins on childhood asthma outcomes through risk factors. Furthermore, the MR analysis identified 73 plasma proteins that exhibited causal associations with at least one risk factor for childhood asthma. Among them, RGAP1 mediates a significant proportion (25.10%) of the risk of childhood asthma through eczema or dermatitis. Finally, a phenotype-wide association study based on these 10 proteins and 1403 diseases provided novel associations between these biomarkers and multiple phenotypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study comprehensively investigated the causal relationship between plasma proteins and childhood asthma, providing novel insights into potential therapeutic targets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12357","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-lung axis and asthma: A historical review on mechanism and future perspective","authors":"Xiu-Ling Song,&nbsp;Juan Liang,&nbsp;Shao-Zhu Lin,&nbsp;Yu-Wei Xie,&nbsp;Chuang-Hong Ke,&nbsp;Dang Ao,&nbsp;Jun Lu,&nbsp;Xue-Mei Chen,&nbsp;Ying-Zhi He,&nbsp;Xiao-Hua Liu,&nbsp;Wen Li","doi":"10.1002/clt2.12356","DOIUrl":"https://doi.org/10.1002/clt2.12356","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gut microbiota are closely related to the development and regulation of the host immune system by regulating the maturation of immune cells and the resistance to pathogens, which affects the host immunity. Early use of antibiotics disrupts the homeostasis of gut microbiota and increases the risk of asthma. Gut microbiota actively interact with the host immune system via the gut-lung axis, a bidirectional communication pathway between the gut and lung. The manipulation of gut microbiota through probiotics, helminth therapy, and fecal microbiota transplantation (FMT) to combat asthma has become a hot research topic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Body</h3>\u0000 \u0000 <p>This review mainly describes the current immune pathogenesis of asthma, gut microbiota and the role of the gut-lung axis in asthma. Moreover, the potential of manipulating the gut microbiota and its metabolites as a treatment strategy for asthma has been discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The gut-lung axis has a bidirectional effect on asthma. Gut microecology imbalance contributes to asthma through bacterial structural components and metabolites. Asthma, in turn, can also cause intestinal damage through inflammation throughout the body. The manipulation of gut microbiota through probiotics, helminth therapy, and FMT can inform the treatment strategies for asthma by regulating the maturation of immune cells and the resistance to pathogens.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140814247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proof-of-concept study of anti-Fel d 1 IgY antibodies in cat food using the MASK-air® app","authors":"Jean Bousquet,&nbsp;Alina Gherasim,&nbsp;Frédéric de Blay,&nbsp;Eve Mathieu-Dupas,&nbsp;Géraldine Batot,&nbsp;Daniel Laune,&nbsp;Bernardo Sousa-Pinto,&nbsp;Torsten Zuberbier,&nbsp;Nhân Pham-Thi,&nbsp;MASK-cat study group","doi":"10.1002/clt2.12353","DOIUrl":"https://doi.org/10.1002/clt2.12353","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>An innovation to better manage cat-allergic patients utilises anti-Fel d 1 IgY antibodies to neutralise Fel d 1 after its production by the cat. However, there is no published study showing its clinical efficacy in humans in a home setting. A longitudinal, open-label, proof-of-concept study was carried out to approach clinical efficacy of the cat food in cat-allergic patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>After a baseline evaluation, the cats ate only the cat food for the following 4 months. Daily evaluation of efficacy was performed for 2 weeks at baseline and after 1, 2 and 3 months of intervention for periods of 2 weeks. The MASK-air app was used daily to assess symptoms, work productivity and medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 49 patients screened, 42 were followed up and 33 (78.5%) reported MASK-air data at all 3 evaluation periods. The primary end point (visual analogue scale [VAS] for global allergy symptoms) was significantly improved (<i>p</i> &lt; 0.0001). All symptoms (VAS nose, eye, and asthma), VAS work and the combined symptom-medication score significantly improved after 1 month. The percentage of uncontrolled days (VAS&gt;20/100) decreased from 64% at baseline to 35% at 1 month (<i>p</i> &lt; 0.0001) and 14% at 3 months. A sensitivity analysis in patients with uncontrolled disease at baseline found similar results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>A cat diet containing anti-Fel d 1 antibodies was able to (i) show decreased allergic symptoms and related outcomes, (ii) inform the design and feasibility of future studies with a control arm and (iii) estimate the sample size of the study.</p>\u0000 \u0000 <p><b>Study registration number</b>: clinicaltrials.gov: <b>NCT05656482</b>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities of chronic rhinosinusitis in children and adults","authors":"Aada Murtomäki,&nbsp;Alma Helevä,&nbsp;Paulus Torkki,&nbsp;Jari Haukka,&nbsp;Anna Julkunen-Iivari,&nbsp;Riikka Lemmetyinen,&nbsp;Mika Mäkelä,&nbsp;Aarno Dietz,&nbsp;Mikko Nuutinen,&nbsp;Sanna Toppila-Salmi","doi":"10.1002/clt2.12354","DOIUrl":"https://doi.org/10.1002/clt2.12354","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nose and paranasal sinuses lasting ≥12 weeks. CRS may exist with (CRSwNP) or without (CRSsNP) nasal polyps. The aim was to evaluate conditions associated with CRS in a randomized hospital cohort. We hypothesized that comorbidities and surgical procedures differ between pediatric and adult patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study consisted of hospital registry data of a random sample of rhinosinusitis patients (age range 0–89 years) with the diagnosis of J32 or J33, correspondingly, registered during outpatient visits from 2005 to 2019 (<i>n</i> = 1461). The covariates of interest were collected from electronic health records based on ICD-10 codes and keyword searches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among pediatric patients (<i>n</i> = 104), the relative proportions of CRSsNP and CRSwNP were 86% and 14% respectively. The relative proportions of adult patients (<i>n</i> = 1357) with CRSsNP and CRSwNP were 60% and 40%, respectively. The following comorbidities significantly differed (<i>p</i> &lt; 0.05) between pediatric and adult populations: allergy, chronic otitis media, and tonsillar diseases. In total, 41 % of the children and 46% of the adults underwent baseline endoscopic sinus surgery (ESS). Additional surgeries of the ear, nose and pharynx were significantly more common among children compared with adults. Risk of revision after baseline ESS was associated (<i>p</i> &lt; 0.05) with allergy, asthma, eosinophilia, CRSwNP, immunodeficiency or its suspicion, non-steroidal anti-inflammatory drug exacerbated respiratory disease, and number of any diseases ≥2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study showed that comorbidities differ between pediatric and adult rhinosinusitis patients, as allergy, asthma and allergy, chronic otitis media, mental health disorders, and tonsils disease were significantly more prevalent among pediatric patients. Children and adults were equally treated with ESS. Notably, children underwent additional surgery on adenoids and tonsils more frequently. The effectiveness of ESS in multimorbid adults should be assessed at an individual level.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consumption of cow's milk formula in the nursery and the development of milk allergy","authors":"Arnon Elizur,&nbsp;Shirel Rachel-Jossefi,&nbsp;Marianna Rachmiel,&nbsp;Eli Eisenberg,&nbsp;Yitzhak Katz","doi":"10.1002/clt2.12352","DOIUrl":"https://doi.org/10.1002/clt2.12352","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The effect of the amount of transient cow's milk formula (CMF) consumed during the first days of life on IgE-cow's milk allergy (IgE-CMA) is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of 58 patients with IgE-CMA was identified from a large scale population-based study of 13,019 infants followed from birth. A group of 116 infants matched for sex and breastfeeding only duration (beyond the nursery period), and another random group of 259 healthy infants were used as controls. Parents were interviewed and the infants' medical records were searched to assess CMF consumption in the nursery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>While 96% of the mothers of the 174 infants (58 with Cow's milk allergy and 116 controls) reported on exclusive breastfeeding during the stay in the nursery, CMF consumption was documented in 96 (55%) of the infants. Of those, most (57; 59%) received one to three feedings, 20 (21%) received four to nine feedings, and 19 (20%) received ≥10 feedings. Fewer formula feeds (1–3) were significantly more common in the allergic group than ≥4 feeds (<i>p</i> = 0.0003) and no feeds at all (<i>p</i> = 0.02) compared to controls (<i>n</i> = 116). Of those exclusively breastfed in the nursery, 13/23 allergic infants (57%) introduced CMF at age 105–194 days (the period with highest-risk for IgE-CMA) compared to 33/98 (34%) from the random control group (<i>n</i> = 259) (<i>p</i> = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Most infants end up receiving few CMF feeds in the nursery. Transient CMF in the nursery is associated with increased risk of IgE-CMA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dilemmas of nomenclature: Web search analysis reveals European preferences in atopic skin diseases","authors":"Hannah Wecker,&nbsp;Stefanie Ziehfreund,&nbsp;Sebastian Sitaru,&nbsp;Emma K. Johansson,&nbsp;Jesper Elberling,&nbsp;Anaïs Doll,&nbsp;Electra Nicolaidou,&nbsp;Emanuele Scala,&nbsp;Michael J. Boffa,&nbsp;Lea Schmidt,&nbsp;Mariusz Sikora,&nbsp;Tiago Torres,&nbsp;Pavel V. Chernyshov,&nbsp;Alexander Zink","doi":"10.1002/clt2.12355","DOIUrl":"https://doi.org/10.1002/clt2.12355","url":null,"abstract":"&lt;p&gt;Atopic dermatitis (AD) or atopic eczema (AE) is a complex chronic inflammatory skin disease with a high prevalence and disease burden.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The nomenclature for this condition has long been the subject of controversial debate within the medical community and even among global experts.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; However, the terminology used not only affects experts, daily clinical practice, and research but especially patients and the general public in terms of their understanding and access to disease-related information.&lt;span&gt;&lt;sup&gt;2-5&lt;/sup&gt;&lt;/span&gt; Given the potential of crowdsourced internet data,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; this study aimed to investigate the use of ‘atopic dermatitis’, ‘atopic eczema’, and their lay terms in internet searches and the content of these searches across 21 European countries in their respective main language.&lt;/p&gt;&lt;p&gt;A total of 71,620,240 AD-related searches, 33,913,480 AE-related searches, and 136,405,350 searches to the respective lay terms were identified across European countries between 02/2019 and 01/2023 using Google Ads Keyword Planner. The top 20 keywords for each country and search term were translated into English and inductively classified into 9 categories: &lt;i&gt;age group&lt;/i&gt;, &lt;i&gt;causes&lt;/i&gt;, &lt;i&gt;comorbidities&lt;/i&gt;, &lt;i&gt;general&lt;/i&gt; information, &lt;i&gt;localisation&lt;/i&gt;, &lt;i&gt;other disease&lt;/i&gt;, &lt;i&gt;others&lt;/i&gt;, &lt;i&gt;symptoms&lt;/i&gt;, and &lt;i&gt;treatment&lt;/i&gt;. Subcategories were formed for recurring keywords, for example, different body localisations. For cross-country comparison, the monthly number of web searches per 100,000 inhabitants was calculated. For detailed methodology, see the Appendix.&lt;/p&gt;&lt;p&gt;Most European countries (&lt;i&gt;n&lt;/i&gt; = 11) had the highest median number of web searches per 100,000 inhabitants for AD-related lay terms, followed by AD (&lt;i&gt;n&lt;/i&gt; = 8) and AE (&lt;i&gt;n&lt;/i&gt; = 2, Figure 1). Analysis revealed common search themes across European countries, including &lt;i&gt;general&lt;/i&gt; disease information, &lt;i&gt;age groups&lt;/i&gt;, &lt;i&gt;localisations&lt;/i&gt;, and &lt;i&gt;treatment&lt;/i&gt;, with slight variations between countries (Figure 2A). The lay term's keywords were often about other diseases. Depending on the search terms, internet queries in some categories focused on different subcategories (Figure 2B). For example, when using the lay term, more countries searched for &lt;i&gt;(natural) remedies&lt;/i&gt; and anogenital localisations, and only AD-related searches included searches for &lt;i&gt;animals&lt;/i&gt;. However, there were also similarities between the search terms, with &lt;i&gt;face&lt;/i&gt;, &lt;i&gt;hands&lt;/i&gt;, and &lt;i&gt;scalp&lt;/i&gt; being the most frequently searched localisations. &lt;i&gt;Age-&lt;/i&gt;related internet searches concerned primarily babies and children, whereas in Austria and Germany, adults were the only search subjects. Search content for lay terms appeared less differentiated than for the other search terms.&lt;/p&gt;&lt;p&gt;Consistent with previous research, both a review study and a global crowdsourced approach found that the term AD was used more freque","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B*58:01 carriers in Korean population; A multicenter cross-sectional case-control study","authors":"","doi":"10.1002/clt2.12351","DOIUrl":"https://doi.org/10.1002/clt2.12351","url":null,"abstract":"<p>M. Y. Kim, J. Yun, D. Y. Kang, T. H. Kim, M. K. Oh, S. Lee, et al. HLA-A* 24: 02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B* 58: 01 carriers in a Korean population; a multicenter cross-sectional case-control study. Clin Transl Allergy. 2022 Sep 15;12(9):e12193.</p><p>This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls. The authors have re-examined the data and confirmed that this correction would not have resulted in any alteration to the results or conclusion of the paper. The figure 2 should be shown as below.</p><p></p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study","authors":"Hui Wang,&nbsp;Jianyu Pang,&nbsp;Yuguan Zhou,&nbsp;Qi Qi,&nbsp;Yuheng Tang,&nbsp;Samina Gul,&nbsp;Miaomiao Sheng,&nbsp;Juhua Dan,&nbsp;Wenru Tang","doi":"10.1002/clt2.12350","DOIUrl":"https://doi.org/10.1002/clt2.12350","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Allergic diseases typically refer to a heterogeneous group of conditions primarily caused by the activation of mast cells or eosinophils, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma. Asthma, AR, and AD collectively affect approximately one-fifth of the global population, imposing a significant economic burden on society. Despite the availability of drugs to treat allergic diseases, they have been shown to be insufficient in controlling relapses and halting disease progression. Therefore, new drug targets are needed to prevent the onset of allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We employed a Mendelian randomization approach to identify potential drug targets for the treatment of allergic diseases. Leveraging 1798 genetic instruments for 1537 plasma proteins from the latest reported Genome-Wide Association Studies (GWAS), we analyzed the GWAS summary statistics of Ferreira MA et al. (nCase = 180,129, nControl = 180,709) using the Mendelian randomization method. Furthermore, we validated our findings in the GWAS data from the FinnGen and UK Biobank cohorts. Subsequently, we conducted sensitivity tests through reverse causal analysis, Bayesian colocalization analysis, and phenotype scanning. Additionally, we performed protein-protein interaction analysis to determine the interaction between causal proteins. Finally, based on the potential protein targets, we conducted molecular docking to identify potential drugs for the treatment of allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;At Bonferroni significance (&lt;i&gt;p&lt;/i&gt; &lt; 3.25 × 10&lt;sup&gt;−5&lt;/sup&gt;), the Mendelian randomization analysis revealed 11 significantly associated protein-allergic disease pairs. Among these, the increased levels of TNFAIP3, ERBB3, TLR1, and IL1RL2 proteins were associated with a reduced risk of allergic diseases, with corresponding odds ratios of 0.82 (0.76–0.88), 0.74 (0.66–0.82), 0.49 (0.45–0.55), and 0.81 (0.75–0.87), respectively. Conversely, increased levels of IL6R, IL1R1, ITPKA, IL1RL1, KYNU, LAYN, and LRP11 proteins were linked to an elevated risk of allergic diseases, with corresponding odds ratios of 1.04 (1.03–1.05), 1.25 (1.18–1.34), 1.48 (1.25–1.75), 1.14 (1.11–1.18), 1.09 (1.05–1.12), 1.96 (1.56–2.47), and 1.05 (1.03–1.07), respectively. Bayesian colocalization analysis suggested that LAYN (coloc.abf-PPH4 = 0.819) and TNFAIP3 (coloc.abf-PPH4 = 0.930) share the same variant associated with allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Our s","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140348563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world drug use in asthma, chronic obstructive pulmonary disease, rhinitis, cough, and cold in Finland from 1990 to 2021: Association with reduced disease burden","authors":"Tiina Mattila,&nbsp;Vesa Jormanainen,&nbsp;Marina Erhola,&nbsp;Tuula Vasankari,&nbsp;Sanna Toppila-Salmi,&nbsp;Fredrik Herse,&nbsp;Riikka-Leena Leskelä,&nbsp;Tari Haahtela","doi":"10.1002/clt2.12340","DOIUrl":"10.1002/clt2.12340","url":null,"abstract":"&lt;p&gt;Asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis are major long-term airway diseases.&lt;span&gt;&lt;sup&gt;1-5&lt;/sup&gt;&lt;/span&gt; Asthma appears in all age groups and COPD causes major morbidity and mortality particularly in smokers.&lt;span&gt;&lt;sup&gt;1, 2, 5&lt;/sup&gt;&lt;/span&gt; Allergic rhinitis and other allergic conditions are often associated with asthma.&lt;span&gt;&lt;sup&gt;3, 4, 6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In Finland, three nationwide respiratory programmes have been implemented since 1994: the Asthma Programme (1994–2004), the COPD Programme (1998–2007), and the Allergy Programme (2008–2018).&lt;span&gt;&lt;sup&gt;4, 6&lt;/sup&gt;&lt;/span&gt; After the 1990s, the burden of asthma, COPD, and allergic conditions has decreased and the prevalence has stabilised.&lt;span&gt;&lt;sup&gt;4, 6&lt;/sup&gt;&lt;/span&gt; Smoking has also decreased.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;International guidelines are available for asthma (since 1995), COPD (since 1997), and chronic rhinitis (since 2005).&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Inhaled short- and long-acting β2 adrenoceptor agonists (LABA), muscarinic receptor antagonists (LAMA), and corticosteroids (ICS) have been used for first-line treatment in asthma and COPD since the 1990s.&lt;span&gt;&lt;sup&gt;1, 2, 4, 8&lt;/sup&gt;&lt;/span&gt; Intranasal corticosteroids have been used in rhinitis for decades.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In the present study, we present consumption (sales) data of medication for asthma, COPD, rhinitis, cough, and cold from 1990 to 2021, and analyse the overall costs of asthma and severe COPD from 1996 to 2018.&lt;/p&gt;&lt;p&gt;Since 1988, the &lt;i&gt;Social Insurance Institution of Finland&lt;/i&gt; (SII) and the &lt;i&gt;Finnish Medicines Agency&lt;/i&gt; (Fimea) have jointly published the &lt;i&gt;Finnish Statistics on Medicine&lt;/i&gt; (FSM), which includes all medications purchased in Finland.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;For sales statistics, medications are listed according to the &lt;i&gt;Anatomical Therapeutic Chemical&lt;/i&gt; groups (R, Respiratory system).&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; We report medication consumption for asthma and COPD (R03; inhaled (R03A-B), systemic (R03DC), and molecular targeted medications (R03DX05, R03DX08–10)), nasal preparations (R01), systemic antihistamines (R06), and medications for cough and cold (R05; such as expectorants (R05C) and cough suppressants (R05D)).&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Medication consumption was followed using the unit &lt;i&gt;Defined Daily Doses&lt;/i&gt; (DDD/1000 population/day) in the Finnish nationwide registries (FSM, SII). The results are presented as annual time series.&lt;/p&gt;&lt;p&gt;Cost analysis was made for asthma and severe COPD comparably to our previous work (data 1996–2018).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; This included only those individuals entitled to special reimbursed medication (same criterions 1996–2018).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The population of Finland was accessed from &lt;i&gt;Statistics Finland,&lt;/i&gt; and it increased from 5.0 million in 1990 to 5.5 million in 2021 (+10%).&lt;/p&gt;&lt;p&gt;Respiratory medications consumption increased from 98 in 1996 to 200 DDD/1000/","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}